Palker T J, Matthews T J, Clark M E, Cianciolo G J, Randall R R, Langlois A J, White G C, Safai B, Snyderman R, Bolognesi D P
Proc Natl Acad Sci U S A. 1987 Apr;84(8):2479-83. doi: 10.1073/pnas.84.8.2479.
A highly immunogenic epitope from a conserved COOH-terminal region of the human immunodeficiency virus (HIV) gp120 envelope protein has been identified with antisera from HIV-seropositive subjects and a synthetic peptide (SP-22) containing 15 amino acids from this region (Ala-Pro-Thr-Lys-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-Arg). Peptide SP-22 absorbed up to 100% of anti-gp120 antibody reactivity from select HIV+ patient sera in immunoblot assays and up to 79% of serum anti-gp120 antibody reactivity in competition RIA. In RIA, 45% of HIV-seropositive subjects had antibodies that bound to peptide SP-22. Human anti-SP-22 antibodies that bound to and were eluted from an SP-22 affinity column reacted with gp120 in RIA and immunoblot assays but did not neutralize HIV or inhibit HIV-induced syncytium formation in vitro, even though these antibodies comprised 70% of all anti-gp120 antibodies in the test serum. In contrast, the remaining 30% of SP-22 nonreactive anti-gp120 antibodies did not react with gp120 in immunoblot assays but did not react in RIA and neutralized HIV in vitro. Thus, approximately 50% of HIV-seropositive patients make high titers of nonneutralizing antibodies to an immunodominant antigen on gp120 defined by SP-22. Moreover, the COOH terminus of gp120 contains the major antigen or antigens identified by human anti-gp120 antibodies in immunoblot assays.
利用来自HIV血清反应阳性个体的抗血清以及一段包含该区域15个氨基酸(丙氨酸-脯氨酸-苏氨酸-赖氨酸-丙氨酸-赖氨酸-精氨酸-精氨酸-缬氨酸-缬氨酸-谷氨酰胺-精氨酸-谷氨酸-赖氨酸-精氨酸)的合成肽(SP-22),已鉴定出人类免疫缺陷病毒(HIV)gp120包膜蛋白保守羧基末端区域的一个高免疫原性表位。在免疫印迹分析中,肽SP-22可吸收高达100%来自特定HIV+患者血清的抗gp120抗体反应性,在竞争RIA中可吸收高达79%的血清抗gp120抗体反应性。在RIA中,45%的HIV血清反应阳性个体具有与肽SP-22结合的抗体。与SP-22亲和柱结合并从该柱上洗脱的人抗SP-22抗体在RIA和免疫印迹分析中与gp120反应,但即使这些抗体占测试血清中所有抗gp120抗体的70%,它们在体外也不能中和HIV或抑制HIV诱导的合胞体形成。相比之下,其余30%不与SP-22反应的抗gp120抗体在免疫印迹分析中不与gp120反应,但在RIA中不反应且在体外可中和HIV。因此,大约50%的HIV血清反应阳性患者针对由SP-22定义的gp120上的一个免疫显性抗原产生高滴度的非中和抗体。此外,gp120的羧基末端包含在免疫印迹分析中被人抗gp120抗体识别的主要一种或多种抗原。